Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial

Abstract Alzheimer’s disease (AD) is characterized by progressive cognitive decline, severe brain atrophy and neuroinflammation. We conducted a randomized, double-blind, placebo-controlled, parallel-group phase 2a clinical trial that tested the safety and efficacy of laromestrocel, a bone-marrow-der...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Brian G. Rash, Kevin Ramdas, Nataliya Agafonova, Eric Naioti, Lisa McClain‐Moss, Zarin Zainul, Brittany Varnado, Kevin Peterson, Michael Brown, Thiago Peixoto Leal, Steven Kopcho, Raul Carballosa, Paayal Patel, Mark Brody, Brad Herskowitz, Ana Fuquay, Savannah Rodriguez, Alan F. Jacobson, Ramón Fernández de León, Michael A. Pfeffer, Julie Schwartzbard, Jeffrey Botbyl, Anthony A. Oliva, Joshua M. Hare
Format: Artigo
Jezik:angleščina
Izdano: 2025
Online dostop:https://doi.org/10.1038/s41591-025-03559-0
Oznake: Označite
Brez oznak, prvi označite!

Internet

https://doi.org/10.1038/s41591-025-03559-0

Podobne knjige/članki